Please assess the completion status of the following clinical trial:

Trial Title: Switch From Dual Regimens Based on Dolutegravir Plus a Reverse Transcriptase Inhibitor to E/C/F/TAF in Virologically Suppressed, HIV-1 Infected Patients (Be-OnE)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \>18 years~2. Willing and able to provide informed consent~3. On a stable (at least 3 months) antiretroviral therapy with DTG 50 mg QD plus one RTI~4. HIV-RNA \<50 copies/mL since at least 6 months~Exclusion Criteria:~1. Active AIDS-defining condition (except Kaposi's sarcoma non requiring systemic chemotherapy)~2. Serious illness requiring systemic treatment and/or hospitalization~3. Current use of immunomodulant or immunosuppressive drugs~4. Need (or will likely need) of treatment with antacids~5. Use of drugs contraindicated with study drugs, according to technical sheets~6. Previous suboptimal therapies with NRTIs or presence of TAMs (type 1 or 2) in previous resistance tests (patients with the 184I/V mutation alone are allowed to enter the study)~7. Resistance or previous virological failure to InSTIs~8. Detectable HCV-RNA~9. Documented allergy to COBI or EVG or FTC or tenofovir.~10. Absolute neutrophil count (ANC) \<500/µL~11. Haemoglobin \<8.0 g/dL~12. Platelet count \<50,000/µL~13. eGFR \<30 mL/min/1.73m2 by CKD-EPI equation~14. Alanine aminotransferase (ALT) more than 5 times the upper limit of normal (ULN)~15. Presence of Child Pugh Class B or C liver cirrhosis.~16. Pregnancy or breastfeeding~17. Woman of childbearing potential who does not agree to adopt highly effective contraception.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Genvoya 150Mg-150Mg-200Mg-10Mg Table (Type: EXPERIMENTAL): switch to the treatment Genvoya 150Mg-150Mg-200Mg-10Mg Table (1 pill every 24 hour)
- Dolutegravir 50 mg plus one RTI (at label dose) (Type: ACTIVE_COMPARATOR): Continuing Dolutegravir 50 mg (1 pill every 24 hours) plus one RTI (at label dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).